






South Bay Pathology Society

Thanks Our Sponsors for Supporting Our 2024 Spring Meeting!!!






















APS Medical Billing

https://www.apsmedbill.com

APS Medical Billing is the leading Pathology and Laboratory billing firm whose foundation stems from a family-owned and operated business. Beginning service in 1960, APS has grown to provide billing and practice management solutions to over 200 pathology practices nationwide. We are located in Toledo, Ohio and employ a staff of more than 300 pathology trained billing professionals. Over 60 years of experience allows APS to define and perfect processes for customization to suit each client's needs.

APS' proprietary system is custom built to suit your complex business arrangements and provide meaningful reporting and feedback. Our expert ICD-10 and CPT Coding, Contract Management, Denial Management and comprehensive Charge Capture system are all customized to ensure you leave no money on the table. For a free consultation, visit www.apsmedbill.com/contact or call (800) 288-8325.

Gerrick Gonzales

Regional Director of Business Development—West gsgonzales@apsmedbill.com

For more information: www.apsmedbill.com



AstraZeneca

https://www.azprecisionmed.com

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Rhodora Estigoy, MBA

Senior Precision Medicine Manager Mobile: 415-425-2440 Rhodora.Estigoy@astrazeneca.com

For more information: https://www.astrazeneca.com/



Blueprint Medicines

https://www.blueprintmedicines.com/about/com

Blueprint Medicines is a global precision therapy company that aims to invent transformative medicines for people with cancer and hematologic disorders. Applying an approach that is both precise and agile, we create therapies that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to translate science rapidly and reproducibly into a broad pipeline of precision therapies. Today, we are delivering our approved medicines to patients in the United States and Europe, and we are globally advancing multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy.

Michael A. Jones, MBA

Precision Medicine Executive—Southwest Mobile: (857) 275-0492 mjones2@blueprintmedicines.com

For more information: www.blueprintmedicines.com



Foundation Medicine

https://www.foundationmedicine.com

Following the completion of the Human Genome Project and the launch of the Cancer Genome Atlas, Foundation Medicine's founders envisioned a world where all cancer patients could benefit from genomic insights at the point of care, and that with a deeper, molecular-level understanding of this disease, we could fundamentally transform the way cancer is treated.

From this idea—democratizing the power of molecular information to benefit patients around the world—Foundation Medicine was born.

We're an essential partner to patients, physicians, researchers, and biopharma organizations navigating the complex landscape of cancer care. Our genomic insights help guide informed decisions about treatment plans and research priorities.

Over the past decade, we've partnered with researchers, biopharma, advocacy organizations, government bodies, health plans, and regulators to validate the use of genomic testing in clinical care, drive awareness among patients and physicians and ultimately support broader access for patients.

The answers we provide through our testing are essential first steps in developing informed treatment strategies and accelerating the development of transformative new therapies.

Nathan O'Brien

Sr. Manager, Corporate Accounts / Northern California Mobile: 927-330-6123 nobrien@foundationmedicine.com

For more information: www.foundationmedicine.com



Mission Statement

At Innovative Science Press, we are dedicated to the advancement of pathologists by producing and disseminating educational text books. We believe that all pathologists deserve access to quality and affordable medical training in order to help their patients. For this reason, our books are written by some of the most prominent in the field and are reasonably priced. We provide steep discounts to residents and fellows to make our products more affordable and donate frequently to the underserved countries.

Survival Guide Series

Although there are many excellent sources for learning diagnostic pathology, those directed at residents, fellows, and practicing pathologists, are too simplified to be practical for daily work with diagnostic pathology, and many other texts assume a foundation of more knowledge than many of us have as we begin to learn about a new area of diagnostic pathology.

This Series is intended to help not only residents and fellows but also practicing pathologists who begin to tackle an organ system that is unfamiliar to them or refresh knowledge on a particular topic. These volumes are practical, concise, and full of excellent illustrations.

We begin with gastrointestinal mucosal biopsies and continue with soft tissue, dermatopathology, endocrine and prostate pathology. Upcoming volumes will cover liver, bone, breast, lung, head and neck, pancreas, gyn, hematopathology, cytopathology, kidney and bladder, testis and penis, and feature a host of authors who are superb educators. We believe you will find this series useful and easy to read.

Elizabeth A. Montgomery, MD Editor-In-Chief Pathology Survival Guides

Mirlinda Caton mqcaton@gmail.com

For more information: https://www.innovativesciencepress.com/



Merck

http://www.merck.com/contact-us/

At Merck, our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer. The potential to bring new hope to people with cancer drives our purpose and our commitment. As part of our focus on cancer, Merck is committed to clinical research with one of the largest development programs in the industry across more than 30 tumor types.

Jeff Jantzen

Senior Precision Medicine Liaison Mobile: 916-765-7510 jeff.jantzen@merck.com

For more information: http://www.merck.com/contact-us/



NeoGenomics

https://neogenomics.com/

NeoGenomics is a premier cancer diagnostic, pharma services, and information services company serving oncologists, pathologists, pharmaceutical companies, and academic centers in their pursuit of providing better futures for people living with cancer.

Our vision brings together uncompromising quality, exceptional service, and innovative solutions. Each member of our team is committed to our mission: Save lives by improving patient CARE through Communication, Accuracy, Reliability, and Efficiency.

NeoGenomics meets you where you are through our network of CAP-accredited, CLIA-certified facilities in the U.S., our global laboratories, as well as our network of national, certified mobile phlebotomy providers.

Caitlin Traylor

Senior Territory Business Manager
San Francisco, CA

Caitlin.Traylor@neogenomics.com

Mobile: 415.218.4356

Client Services: 866.776.5907 option 3

For more information:

https://neogenomics.com/



Simplify real-time blood testing, for everyone, everywhere.

We help health practitioners and patients get rapid blood test diagnostics and information for critical decisions when it matters most.

HemoScreen™

HemoScreen™ harnesses PixCell Medical's Al-assisted Viscoelastic Focusing (VEF) technology to perform lab-grade analysis on a single blood drop sample, as it passes through a unique lab-on-a-cartridge. It is extremely simple to operate, requires no maintenance or calibration, and is fully portable.

Elaine Mellyn

PixCell Medical Inc.
Regional Sales Manager—West elaine.mellyn@hemoscreen.com

Mobile: 310-363-1399

For more information:

https://www.pixcell-medical.com/



Roche Tissue Diagnostics

https://diagnostics.roche.com/global/en/about/roche-tissue-diagnostics.html

Our mission is to improve the lives of all patients afflicted with cancer.

Every year across the globe, more than 14 million people develop cancer, a number that is expected to grow to more than 21 million by the year 2030. Strengthening diagnosis improves chances of survival for the millions of people living with cancer, which means precise, personalized diagnostics are critical as we continue the fight against this deadly disease.

As an innovator of tissue-based diagnostic solutions for patients worldwide, we provide the anatomic pathology lab with a powerful combination of instrumentation, medical value assays and digitally integrated workflow.

Mary Rattay

Pathology Account Executive Northern California - Hawaii Mobile: 317-730-1925 mary.rattay@roche.com

For more information: diagnostics.roche.com